Abstract 52P
Background
The majority of colorectal cancers (CRCs), lung carcinomas (LCs) and melanomas contain hot-spot mutations in driver genes. This study evaluated the feasibility of disease monitoring using individual single-mutation tests for the analysis of circulating tumor DNA (ctDNA) in plasma.
Methods
The study included 49 patients with KRAS/BRAF-mutated CRC, EGFR-mutated LC, or BRAF-mutated melanoma, who received systemic treatment for metastatic disease. Blood samples were collected every 25-30 days; the number of time points varied from 2 to 12 for each patient with the individual follow-up ranging from 29 to 523 days (mean 208.7 ± 18.16). A total of 242 plasma samples were analyzed by droplet digital PCR to quantify ctDNA fragments carrying the corresponding driver mutation.
Results
In 25 patients (49%) no circulating mutant copies were detected in any of the serial samples; 24/25 (96%) of these ctDNA-negative subjects experienced either the reduction of tumor lumps or stable disease during the entire observation period. Twenty-four patients showed variations in the ctDNA status during the disease course. In 21/24 (88%) of these patients, the changes in the concentration of mutated ctDNA closely followed the dynamics of tumor volume as observed by computed tomography (CT). There were instances in which tumor progression was detected by liquid biopsy earlier than by imaging tools. One LC patient demonstrated an emergence of EGFR T790M mutation in the blood 126 days prior to tumor progression as registered by CT; in two other cases, the tumor growth was radiologically documented 23 and 34 days after the appearance of mutated ctDNA in plasma.
Conclusions
Serial ddPCR-based assessment of single driver mutations in ctDNA allows efficient monitoring of the efficacy of therapy in diverse categories of cancer patients. This work has been supported by the Russian Science Foundation grant #17-75-30027.
Editorial acknowledgement
Clinical trial identification
Legal entity responsible for the study
The authors.
Funding
Russian Science Foundation grant #17-75-30027.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
158P - Enhancing the communication of genomic results: Understanding patient and clinician perspectives
Presenter: Eleanor Johnston
Session: Cocktail & Poster Display session
Resources:
Abstract
159P - Precision medicine-based platform to guide the treatment of EML4-ALK fusion lung cancers and other NSCLC
Presenter: Nathan Merrill
Session: Cocktail & Poster Display session
Resources:
Abstract
160P - CICLADES-CE study: Genomic signatures detected in DNA from FFPE samples of patients with advanced or metastatic breast cancers treated with anti-aromatase and CDK4/6 inhibitors
Presenter: Margaux BETZ
Session: Cocktail & Poster Display session
Resources:
Abstract
161P - PDL1 expression and its relation to EML4-ALK gene variants in metastatic lung adenocarcinoma: A single-center real-world experience
Presenter: Santhosh Meedimale
Session: Cocktail & Poster Display session
Resources:
Abstract
163P - Impact of genomic sequencing data on treatment decisions in advanced breast cancer (ABC)
Presenter: Sviatoslav Chekhun
Session: Cocktail & Poster Display session
Resources:
Abstract
164P - Clinical utility of comprehensive molecular profiling tests for advanced gastrointestinal tumors
Presenter: Alexandra Lebedeva
Session: Cocktail & Poster Display session
Resources:
Abstract
165P - Evaluation of the mutational profile in patients with metastatic non-small cell lung carcinoma diagnosed in a tertiary hospital which was performed by NGS method
Presenter: Kankan Deka
Session: Cocktail & Poster Display session
Resources:
Abstract
166P - Targeted next-generation sequencing as reliable detection of genetic profile for cancer treatment to guide oncologists in Pakistan
Presenter: Zeeshan Ahmed
Session: Cocktail & Poster Display session
Resources:
Abstract
167P - Molecular analysis of gastrointestinal stromal tumor (GIST): The experience of Regina Elena National Cancer Institute
Presenter: Andrea Torchia
Session: Cocktail & Poster Display session
Resources:
Abstract
168P - Usefulness of liquid biopsy in the management of patients with advanced or metastatic pancreatic cancer
Presenter: Jorge Iranzo Barreira
Session: Cocktail & Poster Display session
Resources:
Abstract